Background. Colorectal cancer (CRC) is usually diagnosed in the metastatic stage, when chemotherapy and molecularly-targeted therapies, instead of surgery, play the most important therapeutic role. Application of anti-epidermal growth factor receptor (EGFR) therapy requires the analysis of RAS mutation status and only RAS wild-type (wt) patients are qualified for the therapy.
Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer death and one of the most common cancers among both men and women in developed countries. In Poland, approx. 16,000 new cases of CRC are registered every year; more than 10,000 people die (approx. 5,700 men and 4,800 women), and a 5-years overall survival rate among these patients is less than 50%. The early diagnosis of cancers allows the patients to be qualified for surgery. Unfortunately, only small percentage of patients are qualified for surgical resection, and a significant proportion is diagnosed at a late stage, when, in the case of metastatic disease, surgical treatment is only a palliative procedure. Therefore, systemic treatment involving chemotherapy and molecularly targeted therapies plays an important role in the treatment of CRC. [1] [2] [3] For several years, in many European countries, bevacizumab, cetuximab and panitumumab were the molecularly targeted drugs available for advanced CRC. 3 The first one is a monoclonal antibody directed against vascular endothelial growth factor (VEGF), which inhibits angiogenesis and leads to the increase of blood vessel pressure. Two other drugs are monoclonal antibodies against epidermal growth factor receptor (EGFR), and their mechanism of action involves blocking the proliferation signal of tumor cells by inhibiting the EGFR signaling pathway (EGFR/ Pi3K/AKT/mTOR or EGFR/RAS/RAF/MAPK/ERK). 3 Application of these drugs requires an analysis of RAS gene mutations status and only patients with RAS wildtype (wt) are qualified for the therapy. However, more than 40% of patients without common KRAS gene mutations (codon 12 and 13) do not respond to anti-EGFR monoclonal antibody therapies. This resistance can be explained by the presence of mutations in other downstream EGFR signaling pathway effectors, such as BRAF, PIK3CA and NRAS genes, as well as rare KRAS gene mutations (codon 59, 61, 117, 146). [2] [3] [4] In the present study, we assessed the occurrence of driver mutations in KRAS, NRAS, BRAF, and PIK3CA genes in inoperable, locally advanced and advanced CRC patients. We also estimated the association between the mutations incidence and clinical factors, especially tumor localization and stage of the disease.
Material and methods
The study group consisted of 102 CRC patients, including 69 (67.6%) men and 33 (32.4%) women, diagnosed in the Chemotherapy Department, Regional Centre of Oncology, Provincial Specialist Hospital in Łódź, Poland, and in the Oncology and Chemotherapy Unit of the Medical University of Lublin, Poland. The median age was 64 ±9.41 years. All patients had advanced or inoperable mucinous adenocarcinoma CRC. Colorectal cancer grading and subtypes were not possible to assess in all patients due to the availability of only small biopsy specimens. Patients were qualified for anti-EGFR therapy with monoclonal antibodies (cetuximab or panitumumab monotherapy). For the purpose of the study, the following localizations of CRC adenocarcinoma were determined: 1. rectum; 2. sigmoid colon; 3. ascending, transverse and descending colon; and 4. CRC metastases. The clinical characteristics of patients are summarized in Table 1 .
Archival tumor tissue from CRC as formalin-fixed paraffin embedded (FFPE) blocks was available from all patients enrolled in the study. The FFPE blocks were archived in the Department of Clinical Pathomorphology, Medical University of Lublin, Poland, and in Pathology Laboratory Synevo in Łódź, Poland. Mutation analysis was performed after a histological confirmation of cancer and when the presence of more than 10% tumor cells was observed by a pathologist in hematoxylin and eosin (H&E)-stained slides. Genomic DNA was extracted from the FFPE tumor tissue sections using a QIAamp DNA FFPE Tissue Kit (CE-IVD-marked; Qiagen, Hilden, Germany), according to the manufacturer's instructions. DNA concentration and quality was determined by the spectrophotometry method. Estimation of the PIK3CA gene mutations (substitutions Glu542Lys, Glu545Lys, His1047Arg) was conducted using 2 methods based on a quantitative RT-PCR (qPCR). As a screening method, the high resolution melt PCR (HRM-PCR) technique was used. One pair of primers flanked the mutations located in exon 9 (substitutions Glu542Lys, c.1624G>A and Glu545Lys, c.1633G>A), and the 2 nd pair of primers flanked a mutation located in exon 20 (substitution His1047Arg, c.3140A>G). The amplification of the examined region was performed using the Eco RT-PCR device (Illumina, San Diego, USA). Different genotypes of PIK3CA were distinguished according to the normalization data derived from the raw data plots and a difference graph derived from to the normalization data. Comparison of the amplification and melting curves in the positive and negative controls allowed us to distinguish the mutated-type (mt) and wt samples.
In the next step, the allele-specific qPCR (ASP-qPCR) method was used to define the type of mutations. The analysis was performed using the Eco RT-PCR device (Illumina). The wt and mt of the PIK3CA gene were tested in separate reactions with specific forward primers for these variants of the gene. Samples were assessed as positive if amplification in the ASPqPCR was observed both for the mt and for wt of the PIK3CA gene. The samples with late amplification (Ct >32 cycle) of the wt PIK3CA gene were excluded from analysis, and the samples with late amplification (Ct >32 cycle) of the mt region of the PIK3CA gene were assessed as wt. The representative analyses of mutations in PIK3CA genes analyzed by HRM-PCR and by ASP-qPCR were presented in Fig. 1  and 2 , respectively. DNA isolated from the PIK3CA gene mutations positive cell-lines (SW48 cell-line for Glu542Lis; MCF10A cell-line for substitutions Glu545Lys and His1047Arg; Horizon Discovery, Cambridge, UK) served as a positive control. The negative control was determined with DNA isolated from the peripheral blood leukocytes of healthy individuals.
Statistical analysis was performed using STATISTICA, v. 10 (StatSoft Inc., Tulsa, USA). Associations between driver mutation occurrence and clinical factors were examined using Fisher's χ 2 test if the expected values were greater than 5. Fisher's exact test was used if the expected values ranged from 0 to 4. Student's t-test was used for testing the equality of population medians among groups (median age between groups); p-values below 0.05 were considered significant.
Results
The median age was similar in the groups of patients with different clinical characteristics. Forty-six patients demonstrated the presence of any of the examined mutations (45.1%). We found 53 driver mutations in the following genes: 35 mutations in KRAS gene, 4 mutations in NRAS gene, 7 mutations in BRAF gene, and 7 mutations in PIK3CA gene (Fig. 3) .
In 2 cases, the coexistence of 3 of the examined mutations was found. KRAS codon 12 gene (Gly12Val) mutation coexisted with KRAS codon 117 (Lys117X) and PIK3CA codon 542 (Glu542Lys) mutations. In the 2 nd case, KRAS codon 12 gene (Gly12Val) coexisted with KRAS codon 12 (Gly12Cys) and PIK3CA codon 1047 (His1047Arg) mutations. Moreover, in 3 cases we found the coexistence of 2 of the following mutations: KRAS codon 12 (Gly12Asp) mutation coexisted with KRAS codon 12 (Gly12Val) mutation, KRAS codon 12 (Gly12Cys) mutation coexisted with KRAS codon 146 (Ala146X) mutation, and KRAS codon 146 (Ala146X) mutation coexisted with PIK3CA codon 1047 (His1047Arg) mutation.
No differences in the incidence of driver mutations between men (49.28%) and women (45.46%) were found. The occurrence of mutations in KRAS, NRAS and BRAF genes as well as in PIK3CA gene were very similar in men (31.9%, 2.9%, 7.25%, and 7.25%, respectively) and in women (27.3%, 6.1%, 6.1%, and 6.1%, respectively) ( Table 1) .
Depending on the age group, the incidence of KRAS mutations was insignificantly higher, while the incidence of NRAS, BRAF and PIK3CA gene mutations was The melting curve 1 represents mt PIK3CA region, which corresponds to guanine in the position 3140 that needs higher temperature to melt the quantitative real-time polymerase chain reaction (qPCR) products; the melting curve 2 represents wt PIK3CA region, which corresponds to adenine in the position 3140 that needs lower temperature to melt the qPCR products. insignificantly lower in younger patients, when compared to patients ≥64 years old (Table 1) .
There were no statistically significant differences in the incidence of analyzed mutations in rectal and colon cancer. However, only a single mutation of PIK3CA gene and no mutations of NRAS gene were found in rectal cancer. The molecular profile of metastases seems to be different from the primary one. We found that the driver mutations were present significantly more frequently in metastatic tissue compared to primary tissue (p = 0.039; χ 2 = 4.274). Specifically, a significantly higher incidence of KRAS mutations was observed in metastatic tissue (p = 0.014; χ 2 = 5.983) when compared to primary CRC (71.43% vs 27.37%, respectively); similar insignificant differences were observed for NRAS mutations (14.29% vs 3.16%). Moreover, BRAF as well as PIK3CA mutations were observed only in primary tumor tissue ( Table 1) .
The incidence of the examined mutations was also analyzed according to CRC stages, and we found that it was similar for stages II and III of CRC (55.56% and 54.77%, respectively) and for the metastatic stage IV of CRC (41.18%). When the earlier CRC stages were analyzed together, the incidence of PIK3CA mutations was insignificantly higher (11.77%; p = 0.112) in stages II and III of CRC when compared to metastatic CRC (1.96%). On the other hand, NRAS gene mutations were found only in the advanced stage of CRC (7.85%; p = 0.112) ( Table 1) .
Discussion
Nowadays, personalized cancer therapy rapidly becomes the standard care not only for CRC patients, but also in terms of therapies in other cancer patients. New molecular biology techniques are widely used for this purpose. [3] [4] [5] De Sousa et al. distinguished 3 types of colon cancer subtypes using the whole-genome gene expression data and noticed that each type of cancer was associated with a different dominant feature and prognosis for the patient: CCS1 (epithelial type) and CCS2 (microsatellite instability -MSI type) were characterized by a rather good disease outcome, while CCS3 is of the mesenchymal dominant and had a bad prognosis. 6 Nagtegaal and van Krieken proposed that CRC could be molecularly divided into 3 groups based on the epigenetic markers: chromosomal instability (CIN), MSI and CpG island methylation phenotype. 4 It is also postulated that these types of tumors differ in terms of pathology, outcome and response to therapy, but this distinction is not used in clinical practice. 4 From a practical point of view, it is difficult to require such wide molecular testing for CRC. In clinical practice, there are very few genetics laboratories where such broad molecular diagnostics could be performed. Therefore, we promote here an extended panel of RAS gene mutations that could be helpful in a better qualification of CRC patients for molecularly targeted therapy. Furthermore, the use of diagnostic kits (CE-IVD-marked) for the determination of a wide panel of RAS mutations should result in faster test release and a quicker decision in molecularly targeted therapy qualification. It could also help to understand the metastasis process and provide new prognostic factors in patients with CRC.
It is widely known that mutations in KRAS codons 12 and 13 predict the lack of response to anti-EGFR therapies. Vaughn et al. postulated that not only those mutations are responsible, but also additional, rarely tested activating mutations could play a role in treatment resistance. 7 They found that 27.3% of tumors with KRAS wild-type codons 12 and 13 harbored mutation in codons 59, 61, 117, and 147 of the KRAS gene. In RAS wild-type CRC patients, PIK3CA mutations have been associated with a worse clinical outcome and with a negative prediction of response to targeted therapy with anti-EGFR monoclonal antibodies. [7] [8] [9] Authors suggested that accurate testing of RAS genes could be useful in identifying patients who may also be resistant to anti-EGFR therapies. [7] [8] [9] In our examined population, we proved that driver mutations are present in relatively low numbers in CRC patients due to a low incidence of common KRAS mutations (codon 12 and 13). We analyzed 102 CRC patients and 46 (45.1%) of them were found to carry 1 of the analyzed genes aberrations. Moreover, 5 patients were found to carry more than 1 mutation, including patients with coexistence of KRAS and PIK3CA genes mutations. This resulted in the inability to use monoclonal anti-EGFR therapy for those patients, but they had the possibility to be treated in specialized clinical trials.
In the Cetuximab Combined with Irinotecan in FirstLine Therapy for Metastatic Colorectal Cancer (CRYS-TAL)study, a clinical benefit was observed for FOLinic acid-Fluorouracil-IRInotecan (FOLFIRI) scheme together with cetuximab addition in metastatic CRC patients with KRAS codon 12/13 wild-type. Moreover, the patients with the extended RAS wild-type profile derived significant benefit from such therapy, while patients with any RAS mutation did not. 10, 11 Based on the CRYSTAL study results, Van Cutsem et al. postulated that molecular testing for all activating RAS mutations is essential for considering anti-EGFR therapy. 12 Similar results were obtained in Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer (OPUS) (FOLFOX4 and cetuximab) as well as Panitumumab Efficacy in combination with mFOLFOX6 Against bevacizumab plus mFOLFOX6 in mCRC subjects with wild-type KRAS tumors (PEAK) (FOLFOX6 and panitumumab) and PRIME (FOLFOX and panitumumab) studies. [13] [14] [15] There are only few reports in the literature concerning the differences between some genetic alterations and CRC localization. Slattery et al. analyzed the differences in the occurrence of driver mutations in colon and rectal tumors, and found that proximal colon cancers expressed more frequently microsatellite instability and had more KRAS gene mutations than rectal and distal colon tumors, which are more likely to express p53 gene mutations. 16 We analyzed the incidence of driver mutations according to the localization of cancer as well as the type of tumor. When only primary tumors were considered, we found that KRAS driver mutations are more likely to localize in sigmoid colon cancer than in other tumor sites. Moreover, at this tumor location we observed the incidence of different mutations in any gene loci, including a rare mutation in KRAS codon 146, and NRAS codon 61 as well as the PIK3CA Glu542Lys mutations, which could indicate a preferential location of genetic changes at this site. Moreover, the predominant mutations found in rectal tumors were KRAS codon 12 and BRAF Val600X. However, our work was carried out on a relatively small number of patients and confirmation of this thesis requires an extended study group. The coexistence of KRAS with different other mutations could be related to the heterogeneity of the tumor and to the presence of these mutations in different clones of cancer cells. These clinical cases are especially difficult to treat with molecularly targeted therapy.
What is more interesting, we postulated that primary CRC seems to be different in terms of molecular profiling from metastatic tumors. Based on the very preliminary results, we tried to define the molecular profile of CRC metastases, which contain mutations in KRAS and NRAS genes, while they contain neither BRAF nor PIK3CA gene mutations. In contrast, the presence of BRAF and PKI3CA mutations is characteristic for primary, early stages of CRCs.
Driver mutation status correlates not only with the response to anti-EGFR therapies, but also with metastatic spread. According to Lipsyc and Yaeger, the presence of KRAS mutation is associated with an increased risk of lung, brain and bone metastases. BRAF and KRAS genes mutations are rarely associated with the development of CRC liver metastases. BRAF mutation, a poor prognostic factor in metastatic CRC (mCRC), is associated with increased peritoneal and distant lymph node metastases. 17 Moreover, the assessment of mutations in the RAS/BRAF and PIK3CA genes can not only be a predictor of the response to anti-EGFR antibody treatment, but these mutations could also help select patients who would achieve a better response to bevacizumab treatment. 18 In the context of widening the routine molecular diagnostics, the meta-analysis conducted by Therkildsen et al. should be mentioned. 19 The authors suggest that the biomarker analysis beyond KRAS exon 2 should be implemented for clinical benefit prediction from anti-EGFR antibodies in metastatic CRC.
